Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment

Purpose: It has been hypothesized that response to endocrine therapy for breast cancer depends on Her2 and progesterone receptor status, grading, and tumor proliferation rate. In this study, we evaluated factors that are potentially predictive of response and time to progression in patients treated...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2007-08, Vol.13 (15), p.4435-4439
Main Authors: BARTSCH, Rupert, WENZEL, Catharina, ALTORJAI, Gabriela, PLUSCHNIG, Ursula, MADER, Robert M, GNANT, Michael, JAKESZ, Raimund, RUDAS, Margaretha, ZIELINSKI, Christoph C, STEGER, Guenther G
Format: Article
Language:English
Subjects:
Adult
advanced breast cancer
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Agents, Hormonal - therapeutic use
Aromatase Inhibitors - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - drug therapy
Carcinoma, Ductal, Breast - metabolism
Carcinoma, Ductal, Breast - secondary
Carcinoma, Lobular - drug therapy
Carcinoma, Lobular - metabolism
Carcinoma, Lobular - secondary
Disease Progression
endocrine treatment
Estradiol - analogs & derivatives
Estradiol - therapeutic use
Female
fulvestrant
Her2-positive disease
Humans
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Postmenopause
predictive factors
Prospective Studies
Receptor, ErbB-2 - metabolism
Receptors, Progesterone - metabolism
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: It has been hypothesized that response to endocrine therapy for breast cancer depends on Her2 and progesterone receptor status, grading, and tumor proliferation rate. In this study, we evaluated factors that are potentially predictive of response and time to progression in patients treated with fulvestrant. Experimental Design: One hundred fifty-five patients were included and followed prospectively. Patients received fulvestrant at standard dose by i.m. injection. Response was evaluated every 3 months using International Union Against Cancer criteria. Time to progression and overall survival were estimated with the Kaplan-Meier product limit method. A multivariate analysis was done to evaluate factors potentially influencing response and time to progression. Results: We observed a partial response in 19 patients (12.3%), stable disease ≥6 months in 56 patients (36.1%), stable disease >3 months but
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-06-3050